Kineta Pre-Tax Profit Margin 2014-2024 | KANT
Kineta pre-tax profit margin from 2014 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Kineta Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-12-31 |
$0.01B |
$-0.01B |
-280.00% |
| 2023-06-30 |
$0.01B |
$-0.06B |
-1180.00% |
| 2023-03-31 |
$0.00B |
$-0.07B |
-6500.00% |
| 2022-12-31 |
$0.00B |
$-0.06B |
-6400.00% |
| 2022-09-30 |
$0.00B |
0 |
0.00% |
| 2022-06-30 |
$0.01B |
$-0.00B |
-80.00% |
| 2022-03-31 |
$0.01B |
$-0.01B |
-133.33% |
| 2021-12-31 |
$0.01B |
$-0.01B |
-120.00% |
| 2021-09-30 |
$0.01B |
$-0.07B |
-550.00% |
| 2021-06-30 |
$0.01B |
$-0.06B |
-476.92% |
| 2019-03-31 |
$0.01B |
$-0.06B |
-914.29% |
| 2018-09-30 |
$0.01B |
$-0.06B |
-1140.00% |
| 2018-06-30 |
$0.01B |
$-0.05B |
-883.33% |
| 2018-03-31 |
$0.01B |
$-0.06B |
-916.67% |
| 2017-12-31 |
$0.01B |
$-0.06B |
-983.33% |
| 2017-09-30 |
$0.01B |
$-0.06B |
-687.50% |
| 2017-06-30 |
$0.01B |
$-0.05B |
-650.00% |
| 2017-03-31 |
$0.01B |
$-0.04B |
-550.00% |
| 2016-12-31 |
$0.01B |
$-0.04B |
-462.50% |
| 2016-09-30 |
$0.01B |
$-0.03B |
-680.00% |
| 2016-06-30 |
$0.00B |
$-0.03B |
-750.00% |
| 2016-03-31 |
$0.00B |
$-0.03B |
-700.00% |
| 2015-12-31 |
$0.00B |
$-0.03B |
-650.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
